Personalizing Risk Stratification for Sudden Death in Dilated Cardiomyopathy-Reference-Cited by-同舟云学术

Personalizing Risk Stratification for Sudden Death in Dilated Cardiomyopathy

Published:2017-07-11 Issue:2 Volume:136 Page:215-231
ISSN:0009-7322
Container-title:Circulation
language:en
Short-container-title:Circulation

Author:

Halliday Brian P.¹,Cleland John G.F.¹,Goldberger Jeffrey J.¹,Prasad Sanjay K.¹

Affiliation:

1. From CMR Unit and Cardiovascular Biomedical Research Unit, Royal Brompton Hospital, London, United Kingdom (B.P.H., S.K.P.), National Heart and Lung Institute Imperial College, London, United Kingdom (B.P.H., S.K.P., J.G.F.C.); Robertson Centre for Biostatistics, University of Glasgow, United Kingdom (J.G.F.C.); and Leonard M. Miller School of Medicine, University of Miami, FL (J.J.G.).

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine

Reference97 articles.

1. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases

2. Dilated cardiomyopathy: the complexity of a diverse genetic architecture

3. Primary Prevention of Sudden Cardiac Death in Idiopathic Dilated Cardiomyopathy

4. Amiodarone versus implantable cardioverter-defibrillator:randomized trial in patients with nonischemicdilated cardiomyopathy and asymptomaticnonsustained ventricular tachycardia—AMIOVIRT

5. Amiodarone or an Implantable Cardioverter–Defibrillator for Congestive Heart Failure

Cited by 183 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Uncertain Benefit from Implantable Cardioverter-Defibrillators in Nonischemic Cardiomyopathy;Heart Failure Clinics;2024-10

2. Difficulties in detecting and differential diagnosis of dilated cardiomyopathy in young children;Meditsinskiy sovet = Medical Council;2024-08-06

3. Cardiomyopathy and Sudden Cardiac Death: Bridging Clinical Practice with Cutting-Edge Research;Biomedicines;2024-07-18

4. Epigenome-wide association study for dilated cardiomyopathy in left ventricular heart tissue identifies putative gene sets associated with cardiac development and early indicators of cardiac risk;2024-07-17

5. Protein phosphatase 2A anchoring disruptor gene therapy for familial dilated cardiomyopathy;Molecular Therapy - Methods & Clinical Development;2024-06